Compare United States Copper Index Fund (CPER) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Neurocrine Biosciences Inc — how do they compare? United States Copper Index Fund trades at $39.91 (market cap $716.81M), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Neurocrine Biosciences Inc is far larger — about 20.4× United States Copper Index Fund's market cap, and United States Copper Index Fund is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and Neurocrine Biosciences Inc for 23 Days on average.
| CPER | NBIX | |
|---|---|---|
Market Cap | $716.81M | $14.60B |
Volume | 388,730 | 1,075,694 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $185.50 |
52-Week Low | $30.27 | $123.10 |
Typical Hold Time | 48 Days | 23 Days |
Enterprise Value | — | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER trades at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish moving averages but neutral oscillators, with key support at $39. Recent news highlights strong copper demand driven by AI infrastructure, though some articles note price volatility. Financial ratios are unavailable in the provided data.
The outlook for CPER is mixed, balancing positive copper demand trends against near-term price pressure. Investment opportunity lies in exposure to the essential metal for AI and electrification, but risks include commodity price swings and operational challenges in the mining sector. Investors should weigh sector momentum against inherent volatility.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
